Stryker Corporation $SYK Shares Purchased by PDS Planning Inc

PDS Planning Inc lifted its holdings in Stryker Corporation (NYSE:SYK) by 42.0% in the second quarter, Holdings Channel reports. The firm owned 2,516 shares of the medical technology company’s stock after buying an additional 744 shares during the period. PDS Planning Inc’s holdings in Stryker were worth $996,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cascade Investment Group Inc. lifted its position in Stryker by 6.3% during the 2nd quarter. Cascade Investment Group Inc. now owns 588 shares of the medical technology company’s stock worth $233,000 after acquiring an additional 35 shares during the period. L. Roy Papp & Associates LLP lifted its position in Stryker by 1.2% during the 2nd quarter. L. Roy Papp & Associates LLP now owns 62,910 shares of the medical technology company’s stock worth $24,889,000 after acquiring an additional 726 shares during the period. Baskin Financial Services Inc. lifted its position in Stryker by 0.6% during the 2nd quarter. Baskin Financial Services Inc. now owns 112,795 shares of the medical technology company’s stock worth $44,625,000 after acquiring an additional 674 shares during the period. Commerzbank Aktiengesellschaft FI lifted its position in Stryker by 0.3% during the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 60,899 shares of the medical technology company’s stock worth $24,093,000 after acquiring an additional 160 shares during the period. Finally, Coordinated Financial Services Inc. acquired a new stake in Stryker during the 2nd quarter worth about $751,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity at Stryker

In other Stryker news, insider Viju Menon sold 500 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares in the company, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the sale, the director owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Stryker Price Performance

Shares of Stryker stock opened at $364.77 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The business has a 50-day moving average price of $380.25 and a 200 day moving average price of $378.75. The firm has a market cap of $139.46 billion, a PE ratio of 48.31, a P/E/G ratio of 2.67 and a beta of 0.94.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating the consensus estimate of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. During the same quarter in the previous year, the business earned $2.81 EPS. Stryker’s revenue for the quarter was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Sell-side analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s payout ratio is 44.50%.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Needham & Company LLC lifted their price target on Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a research note on Friday, September 26th. Evercore ISI reduced their price objective on Stryker from $418.00 to $410.00 and set an “outperform” rating for the company in a research note on Tuesday. BTIG Research reiterated a “buy” rating on shares of Stryker in a research note on Monday, July 14th. Finally, Wells Fargo & Company lifted their price objective on Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a research note on Friday, August 1st. Fifteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $430.10.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.